Publications by authors named "Alberto A Gabizon"

Claim this Profile
C
Cancer nanomedicine from a clinician-scientist perspective: Lessons and prospects.
Alberto A Gabizon

J Control Release· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective.
Alberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi, Ninh M La-Beck

BMJ Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas.
Antonia Charalambous, Fotios Mpekris, Myrofora Panagi, Chrysovalantis Voutouri, Christina Michael, Alberto A Gabizon

Mol Cancer Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.
Md Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Shmeeda, Raja Reddy Kallem, Alberto A Gabizon

Biomolecules· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
Md Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Shmeeda, Konstantin Adamsky, Alberto A Gabizon

Nanotheranostics· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational considerations in nanomedicine: The oncology perspective.
Alberto A Gabizon, Rafael T M de Rosales, Ninh M La-Beck

Adv Drug Deliv Rev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.
Ninh M La-Beck, Xinli Liu, Hilary Shmeeda, Claire Shudde, Alberto A Gabizon

Semin Cancer Biol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Alberto A Gabizon, Esther Tahover, Talia Golan, Ravit Geva, Ruth Perets

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts.
Esben Christensen, Jonas R Henriksen, Jesper T Jørgensen, Yasmine Amitay, Hilary Shmeeda, Alberto A Gabizon

Int J Nanomedicine· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience.
Esther Tahover, Rachel Bar-Shalom, Eli Sapir, Raphael Pfeffer, Igor Nemirovsky, Alberto A Gabizon

Front Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.
Robin Rajan, Manoj K Sabnani, Vikram Mavinkurve, Hilary Shmeeda, Hossein Mansouri, Alberto A Gabizon

J Control Release· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy.
Ninh M La-Beck, Alberto A Gabizon

Front Immunol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Xi Tian, Samuel B Warner, Kyle T Wagner, Joseph M Caster, Tian Zhang, Alberto A Gabizon

Int J Radiat Oncol Biol Phys· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Alberto A Gabizon, Yogita Patil, Ninh M La-Beck

Drug Resist Updat· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Talia Golan, Tal Grenader, Patricia Ohana, Yasmine Amitay, Hilary Shmeeda, Alberto A Gabizon

Cancer Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
Esther Tahover, Yogita P Patil, Alberto A Gabizon

Anticancer Drugs· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses.
Manoj K Sabnani, Robin Rajan, Bradley Rowland, Vikram Mavinkurve, Laurence M Wood, Alberto A Gabizon

Nanomedicine· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.
Nicola J Nasser, Mira Na'amad, Ido Weinberg, Alberto A Gabizon

Anticancer Drugs· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Rebecca Soloman, Alberto A Gabizon

Clin Lymphoma Myeloma· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pros and cons of the liposome platform in cancer drug targeting.
Alberto A Gabizon, Hilary Shmeeda, Samuel Zalipsky

J Liposome Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Alberto A Gabizon, Dinah Tzemach, Aviva T Horowitz, Hilary Shmeeda, Jerry Yeh

Clin Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.
Alberto A Gabizon, Olga Lyass, Gerald J Berry, Mark Wildgust

Cancer Invest· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
David S Alberts, Franco M Muggia, James Carmichael, Eric P Winer, Mohammad Jahanzeb, Alberto A Gabizon

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Nicholas J Robert, Charles L Vogel, I Craig Henderson, Joseph A Sparano, Melvin R Moore, Alberto A Gabizon

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac safety of liposomal anthracyclines.
Michael S Ewer, Francis J Martin, Craig Henderson, Charles L Shapiro, Robert S Benjamin, Alberto A Gabizon

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis